Targeting Precursor N-cadherin to Eliminate Docetaxel-resistant, Castration-resistant Prostate Cancer Using an Animal Model
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
Duke University Medical Center
Award Date
Award Amount
99,948
Program Name
Biotechnology Innovation Grant
Program Category
Research and Equipment Support
Principal Investigator
Robin Bachelder
Fiscal Year
2018
Region
Research Triangle
Project Description:
Docetaxel, a chemotherapy drug, prolongs the life of men with metastatic prostate cancer. However, nearly all of the men treated with docetaxel develop docetaxel-resistant disease within 6 months, which is often fatal. Using an animal model, this project will test the effectiveness of a novel therapy for eliminating docetaxel-resistant prostate cancer cells.